United Therapeutics, an American publicly traded biotechnology company, completed the acquisition of Miromatrix Medical, a life sciences company focused on the development of bioengineered organs composed of human cells, for $91m. “At United Therapeutics, we are determined to rectify the severe shortage of transplantable organs,” Martine Rothblatt, Ph.D., United Therapeutics Chairperson and Chief Executive Officer.